Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2006-07-18
2006-07-18
Shukla, Ram R. (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S320100, C435S325000, C435S457000
Reexamination Certificate
active
07078030
ABSTRACT:
Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.
REFERENCES:
Parr MJ, Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector, 1997, Nature, Medicine, vol. 3, pp. 1145-1149.
Parekh-Olmedo H, Gene therapy progress and prospects: targeted gene repair, 2005, Gene Therapy, vol. 12, pp. 639-646.
Verma IM, Gene Therapy: Twenty-first century medicine, 2005, Annu. Rev. Biochem. vol. 74, pp. 711-738.
Concalves M, A concise peer into the background, initial thoughts, and practices of human gene therapy, 2005, BioEssays, vol. 27, pp. 506-517.
Schmid, SI, Bipartite structure and functional independence of adenovirus type 5 packaging elements, 1997, J. of Virology, vol. 71, pp. 3375-3384.
Fattaey Ali
Hermiston Terry
Johnson Leisa
Laquerre Sylvie
Shen Jerry Yuqiao
Giotta Gregory
Montanari David A.
Onyx Pharmaceuticals, Inc
Shukla Ram R.
LandOfFree
Oncolytic adenovirus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oncolytic adenovirus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oncolytic adenovirus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3541266